{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:25:40Z","timestamp":1769732740946,"version":"3.49.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1431\/16"],"award-info":[{"award-number":["1431\/16"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inhibition of extracellular glutamate (Glu) release decreases proliferation and invasion, induces apoptosis, and inhibits melanoma metastatic abilities. Previous studies have shown that Blood-glutamate scavenging (BGS), a novel treatment approach, has been found to be beneficial in attenuating glioblastoma progression by reducing brain Glu levels. Therefore, in this study we evaluated the ability of BGS treatment to inhibit brain metastatic melanoma progression in-vivo. RET melanoma cells were implanted in C56BL\/6J mice to induce brain melanoma tumors followed by treatment with BGS or vehicle administered for fourteen days. Bioluminescent imaging was conducted to evaluate tumor growth, and plasma\/CSF Glu levels were monitored throughout. Immunofluorescence staining of Ki67 and 53BP1 was used to analyze tumor cell proliferation and DNA double-strand breaks. In addition, we analyzed CD8, CD68, CD206, p-STAT1 and iNOS expression to evaluate alterations in tumor micro-environment and anti-tumor immune response due to treatment. Our results show that BGS treatment reduces CSF Glu concentration and consequently melanoma growth in-vivo by decreasing tumor cell proliferation and increasing pro-apoptotic signaling in C56BL\/6J mice. Furthermore, BGS treatment supported CD8<jats:sup>+<\/jats:sup> cell recruitment and CD68<jats:sup>+<\/jats:sup> macrophage invasion. These findings suggest that BGS can be of potential therapeutic relevance in the treatment of metastatic melanoma.<\/jats:p>","DOI":"10.1038\/s41598-021-94183-8","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T10:03:18Z","timestamp":1626688998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Blood glutamate scavengers increase pro-apoptotic signaling and reduce metastatic melanoma growth in-vivo"],"prefix":"10.1038","volume":"11","author":[{"given":"Yona","family":"Goldshmit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Perelroizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Yakovchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeni","family":"Banyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Benbenishty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Blinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Shalom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Ruban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"94183_CR1","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/nm0901-1010","volume":"7","author":"T Takano","year":"2001","unstructured":"Takano, T. et al. Glutamate release promotes growth of malignant gliomas. Nat. Med. 7, 1010\u20131015. https:\/\/doi.org\/10.1038\/nm0901-1010 (2001).","journal-title":"Nat. Med."},{"key":"94183_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.tins.2003.08.007","volume":"26","author":"H Sontheimer","year":"2003","unstructured":"Sontheimer, H. Malignant gliomas: Perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci. 26, 543\u2013549. https:\/\/doi.org\/10.1016\/j.tins.2003.08.007 (2003).","journal-title":"Trends Neurosci."},{"key":"94183_CR3","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00018-013-1521-z","volume":"71","author":"SM Robert","year":"2014","unstructured":"Robert, S. M. & Sontheimer, H. Glutamate transporters in the biology of malignant gliomas. Cell Mol. Life Sci. 71, 1839\u20131854. https:\/\/doi.org\/10.1007\/s00018-013-1521-z (2014).","journal-title":"Cell Mol. Life Sci."},{"key":"94183_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/glia.21113","volume":"59","author":"J de Groot","year":"2011","unstructured":"de Groot, J. & Sontheimer, H. Glutamate and the biology of gliomas. Glia 59, 1181\u20131189. https:\/\/doi.org\/10.1002\/glia.21113 (2011).","journal-title":"Glia"},{"key":"94183_CR5","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s10637-012-9799-5","volume":"30","author":"A Ruban","year":"2012","unstructured":"Ruban, A., Berkutzki, T., Cooper, I., Mohar, B. & Teichberg, V. I. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Investig. New Drugs 30, 2226\u20132235. https:\/\/doi.org\/10.1007\/s10637-012-9799-5 (2012).","journal-title":"Investig. New Drugs"},{"key":"94183_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbrc.2009.10.168","volume":"391","author":"MK Sharma","year":"2010","unstructured":"Sharma, M. K., Seidlitz, E. P. & Singh, G. Cancer cells release glutamate via the cystine\/glutamate antiporter. Biochem. Biophys. Res. Commun. 391, 91\u201395. https:\/\/doi.org\/10.1016\/j.bbrc.2009.10.168 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"94183_CR7","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.1074\/jbc.M117.798405","volume":"292","author":"P Koppula","year":"2017","unstructured":"Koppula, P., Zhang, Y., Shi, J., Li, W. & Gan, B. The glutamate\/cystine antiporter SLC7A11\/xCT enhances cancer cell dependency on glucose by exporting glutamate. J. Biol. Chem. 292, 14240\u201314249. https:\/\/doi.org\/10.1074\/jbc.M117.798405 (2017).","journal-title":"J. Biol. Chem."},{"key":"94183_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bcp.2015.08.091","volume":"98","author":"T Gelb","year":"2015","unstructured":"Gelb, T. et al. Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells. Biochem. Pharmacol. 98, 182\u2013189. https:\/\/doi.org\/10.1016\/j.bcp.2015.08.091 (2015).","journal-title":"Biochem. Pharmacol."},{"key":"94183_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/pcmr.12207","volume":"27","author":"BA Wall","year":"2014","unstructured":"Wall, B. A. et al. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res 27, 263\u2013274. https:\/\/doi.org\/10.1111\/pcmr.12207 (2014).","journal-title":"Pigment Cell Melanoma Res"},{"key":"94183_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/1541-7786.MCR-12-0158","volume":"10","author":"J Wangari-Talbot","year":"2012","unstructured":"Wangari-Talbot, J., Wall, B. A., Goydos, J. S. & Chen, S. Functional effects of GRM1 suppression in human melanoma cells. Mol. Cancer Res. 10, 1440\u20131450. https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0158 (2012).","journal-title":"Mol. Cancer Res."},{"key":"94183_CR11","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-06-3665","volume":"67","author":"J Namkoong","year":"2007","unstructured":"Namkoong, J. et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 67, 2298\u20132305. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3665 (2007).","journal-title":"Cancer Res."},{"key":"94183_CR12","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1038\/onc.2008.329","volume":"27","author":"Y Ohtani","year":"2008","unstructured":"Ohtani, Y. et al. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 27, 7162\u20137170. https:\/\/doi.org\/10.1038\/onc.2008.329 (2008).","journal-title":"Oncogene"},{"key":"94183_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1158\/0008-5472.CAN-18-1500","volume":"79","author":"R Shah","year":"2019","unstructured":"Shah, R., Singh, S. J., Eddy, K., Filipp, F. V. & Chen, S. Concurrent targeting of glutaminolysis and metabotropic glutamate receptor 1 (GRM1) reduces glutamate bioavailability in GRM1(+) melanoma. Cancer Res. 79, 1799\u20131809. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1500 (2019).","journal-title":"Cancer Res."},{"key":"94183_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/ng1148","volume":"34","author":"PM Pollock","year":"2003","unstructured":"Pollock, P. M. et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108\u2013112. https:\/\/doi.org\/10.1038\/ng1148 (2003).","journal-title":"Nat. Genet."},{"key":"94183_CR15","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-11-1217","volume":"18","author":"TD Prickett","year":"2012","unstructured":"Prickett, T. D. & Samuels, Y. Molecular pathways: Dysregulated glutamatergic signaling pathways in cancer. Clin. Cancer Res. 18, 4240\u20134246. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1217 (2012).","journal-title":"Clin. Cancer Res."},{"key":"94183_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler, I. J. The pathogenesis of cancer metastasis: The \u201cseed and soil\u201d hypothesis revisited. Nat. Rev. Cancer 3, 453\u2013458. https:\/\/doi.org\/10.1038\/nrc1098 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"94183_CR17","first-page":"572","volume":"7","author":"A Sandru","year":"2014","unstructured":"Sandru, A., Voinea, S., Panaitescu, E. & Blidaru, A. Survival rates of patients with metastatic malignant melanoma. J. Med. Life 7, 572\u2013576 (2014).","journal-title":"J. Med. Life"},{"key":"94183_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12885-018-4374-x","volume":"18","author":"E Vosoughi","year":"2018","unstructured":"Vosoughi, E. et al. Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer 18, 490. https:\/\/doi.org\/10.1186\/s12885-018-4374-x (2018).","journal-title":"BMC Cancer"},{"key":"94183_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4161\/cbt.9.6.10898","volume":"9","author":"KS Brocke","year":"2010","unstructured":"Brocke, K. S. et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol. Ther. 9, 455\u2013468. https:\/\/doi.org\/10.4161\/cbt.9.6.10898 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"94183_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/aja.2012.145","volume":"15","author":"S Koochekpour","year":"2013","unstructured":"Koochekpour, S. Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer. Asian J. Androl. 15, 212\u2013213. https:\/\/doi.org\/10.1038\/aja.2012.145 (2013).","journal-title":"Asian J. Androl."},{"key":"94183_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neuropharm.2016.02.011","volume":"115","author":"LJ Yu","year":"2017","unstructured":"Yu, L. J., Wall, B. A., Wangari-Talbot, J. & Chen, S. Metabotropic glutamate receptors in cancer. Neuropharmacology 115, 193\u2013202. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.02.011 (2017).","journal-title":"Neuropharmacology"},{"key":"94183_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/CCO.0b013e3283436e79","volume":"23","author":"J Weber","year":"2011","unstructured":"Weber, J. Immunotherapy for melanoma. Curr. Opin. Oncol. 23, 163\u2013169. https:\/\/doi.org\/10.1097\/CCO.0b013e3283436e79 (2011).","journal-title":"Curr. Opin. Oncol."},{"key":"94183_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0b013e328343ece0","volume":"21","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof, S. et al. Restoration of tumor equilibrium after immunotherapy for advanced melanoma: Three illustrative cases. Melanoma Res. 21, 152\u2013159. https:\/\/doi.org\/10.1097\/CMR.0b013e328343ece0 (2011).","journal-title":"Melanoma Res."},{"key":"94183_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10060410","author":"R Fonti","year":"2020","unstructured":"Fonti, R., Pellegrino, S., Mainolfi, C. G., Matano, E. & Del Vecchio, S. Brain metastases unresponsive to immunotherapy detected by 18F-FDG-PET\/CT in a patient with melanoma. Diagnostics https:\/\/doi.org\/10.3390\/diagnostics10060410 (2020).","journal-title":"Diagnostics"},{"key":"94183_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000763","author":"E Le Rhun","year":"2020","unstructured":"Le Rhun, E. et al. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. ESMO Open https:\/\/doi.org\/10.1136\/esmoopen-2020-000763 (2020).","journal-title":"ESMO Open"},{"key":"94183_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/imt-2018-0111","volume":"11","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Endres, S. & Kobold, S. Enhancing tumor T cell infiltration to enable cancer immunotherapy. Immunotherapy 11, 201\u2013213. https:\/\/doi.org\/10.2217\/imt-2018-0111 (2019).","journal-title":"Immunotherapy"},{"key":"94183_CR27","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-17-2769","volume":"24","author":"RA Buerki","year":"2018","unstructured":"Buerki, R. A., Chheda, Z. S. & Okada, H. Immunotherapy of primary brain tumors: Facts and hopes. Clin. Cancer Res. 24, 5198\u20135205. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2769 (2018).","journal-title":"Clin. Cancer Res."},{"key":"94183_CR28","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart, D. et al. Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking. Proc. Natl. Acad. Sci. USA 115, E1540\u2013E1549. https:\/\/doi.org\/10.1073\/pnas.1714089115 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"94183_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.bbrc.2004.04.053","volume":"318","author":"G Lombardi","year":"2004","unstructured":"Lombardi, G. et al. Glutamate modulation of human lymphocyte growth: In vitro studies. Biochem. Biophys. Res. Commun. 318, 496\u2013502. https:\/\/doi.org\/10.1016\/j.bbrc.2004.04.053 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"94183_CR30","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.4049\/jimmunol.170.8.4362","volume":"170","author":"Y Ganor","year":"2003","unstructured":"Ganor, Y., Besser, M., Ben-Zakay, N., Unger, T. & Levite, M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J. Immunol. 170, 4362\u20134372 (2003).","journal-title":"J. Immunol."},{"key":"94183_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00702-014-1167-5","volume":"121","author":"Y Ganor","year":"2014","unstructured":"Ganor, Y. & Levite, M. The neurotransmitter glutamate and human T cells: Glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. J. Neural Transm. 121, 983\u20131006. https:\/\/doi.org\/10.1007\/s00702-014-1167-5 (2014).","journal-title":"J. Neural Transm."},{"key":"94183_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1471-4159.2003.01972.x","volume":"87","author":"M Gottlieb","year":"2003","unstructured":"Gottlieb, M., Wang, Y. & Teichberg, V. I. Blood-mediated scavenging of cerebrospinal fluid glutamate. J. Neurochem. 87, 119\u2013126. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.01972.x (2003).","journal-title":"J. Neurochem."},{"key":"94183_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/jcbfm.2011.121","volume":"32","author":"K Cohen-Kashi-Malina","year":"2012","unstructured":"Cohen-Kashi-Malina, K., Cooper, I. & Teichberg, V. I. Mechanisms of glutamate efflux at the blood\u2013brain barrier: Involvement of glial cells. J. Cereb. Blood Flow Metab. 32, 177\u2013189. https:\/\/doi.org\/10.1038\/jcbfm.2011.121 (2012).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"94183_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.neuroscience.2008.02.075","volume":"158","author":"VI Teichberg","year":"2009","unstructured":"Teichberg, V. I., Cohen-Kashi-Malina, K., Cooper, I. & Zlotnik, A. Homeostasis of glutamate in brain fluids: An accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 158, 301\u2013308. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.02.075 (2009).","journal-title":"Neuroscience"},{"key":"94183_CR35","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.3390\/ijms16023226","volume":"16","author":"A Ruban","year":"2015","unstructured":"Ruban, A., Biton, I. E., Markovich, A. & Mirelman, D. MRS of brain metabolite levels demonstrates the ability of scavenging of excess brain glutamate to protect against nerve agent induced seizures. Int. J. Mol. Sci. 16, 3226\u20133236. https:\/\/doi.org\/10.3390\/ijms16023226 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"94183_CR36","doi-asserted-by":"publisher","first-page":"e992","DOI":"10.1038\/cddis.2013.507","volume":"5","author":"M Perez-Mato","year":"2014","unstructured":"Perez-Mato, M. et al. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis. 5, e992. https:\/\/doi.org\/10.1038\/cddis.2013.507 (2014).","journal-title":"Cell Death Dis."},{"key":"94183_CR37","doi-asserted-by":"publisher","DOI":"10.3171\/2020.4.SPINE20302","author":"Y Goldshmit","year":"2020","unstructured":"Goldshmit, Y., Banyas, E., Bens, N., Yakovchuk, A. & Ruban, A. Blood glutamate scavengers and exercises as an effective neuroprotective treatment in mice with spinal cord injury. J. Neurosurg. Spine https:\/\/doi.org\/10.3171\/2020.4.SPINE20302 (2020).","journal-title":"J. Neurosurg. Spine"},{"key":"94183_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9794-x","author":"A Ruban","year":"2012","unstructured":"Ruban, A., Berkutzki, T., Cooper, I., Mohar, B. & Teichberg, V. I. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. InvestIG. New Drugs https:\/\/doi.org\/10.1007\/s10637-012-9794-x (2012).","journal-title":"InvestIG. New Drugs"},{"key":"94183_CR39","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1089\/neu.2017.5524","volume":"35","author":"Y Goldshmit","year":"2018","unstructured":"Goldshmit, Y. et al. Blood glutamate scavenger as a novel neuroprotective treatment in spinal cord injury. J. Neurotrauma 35, 2581\u20132590. https:\/\/doi.org\/10.1089\/neu.2017.5524 (2018).","journal-title":"J. Neurotrauma"},{"key":"94183_CR40","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","volume":"23","author":"B Jovanovic","year":"2017","unstructured":"Jovanovic, B. et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II\/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. Clin. Cancer Res. 23, 4035\u20134045. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3055 (2017).","journal-title":"Clin. Cancer Res."},{"key":"94183_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1023\/a:1015739130208","volume":"57","author":"F Kayaselcuk","year":"2002","unstructured":"Kayaselcuk, F., Zorludemir, S., Gumurduhu, D., Zeren, H. & Erman, T. PCNA and Ki-67 in central nervous system tumors: Correlation with the histological type and grade. J. Neurooncol. 57, 115\u2013121. https:\/\/doi.org\/10.1023\/a:1015739130208 (2002).","journal-title":"J. Neurooncol."},{"key":"94183_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1083\/jcb.153.3.613","volume":"153","author":"I Rappold","year":"2001","unstructured":"Rappold, I., Iwabuchi, K., Date, T. & Chen, J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J. Cell Biol. 153, 613\u2013620. https:\/\/doi.org\/10.1083\/jcb.153.3.613 (2001).","journal-title":"J. Cell Biol."},{"key":"94183_CR43","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1083\/jcb.151.7.1381","volume":"151","author":"LB Schultz","year":"2000","unstructured":"Schultz, L. B., Chehab, N. H., Malikzay, A. & Halazonetis, T. D. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151, 1381\u20131390. https:\/\/doi.org\/10.1083\/jcb.151.7.1381 (2000).","journal-title":"J. Cell Biol."},{"key":"94183_CR44","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1128\/mcb.23.7.2556-2563.2003","volume":"23","author":"IM Ward","year":"2003","unstructured":"Ward, I. M., Minn, K., van Deursen, J. & Chen, J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell Biol. 23, 2556\u20132563. https:\/\/doi.org\/10.1128\/mcb.23.7.2556-2563.2003 (2003).","journal-title":"Mol. Cell Biol."},{"key":"94183_CR45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s0887-2333(03)00024-9","volume":"17","author":"S Manakova","year":"2003","unstructured":"Manakova, S., Puttonen, K. A., Raasmaja, A. & Mannisto, P. T. Ara-C induces apoptosis in monkey fibroblast cells. Toxicol. In Vitro 17, 367\u2013373. https:\/\/doi.org\/10.1016\/s0887-2333(03)00024-9 (2003).","journal-title":"Toxicol. In Vitro"},{"key":"94183_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijsu.2018.02.055","volume":"52","author":"KH Huang","year":"2018","unstructured":"Huang, K. H. et al. Caspase-3, a key apoptotic protein, as a prognostic marker in gastric cancer after curative surgery. Int. J. Surg. 52, 258\u2013263. https:\/\/doi.org\/10.1016\/j.ijsu.2018.02.055 (2018).","journal-title":"Int. J. Surg."},{"key":"94183_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 12, 298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"94183_CR48","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/cncr.23712","volume":"113","author":"O Kawai","year":"2008","unstructured":"Kawai, O. et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387\u20131395. https:\/\/doi.org\/10.1002\/cncr.23712 (2008).","journal-title":"Cancer"},{"key":"94183_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela, N. R., Liu, S. & Zhang, Y. Fates of CD8+ T cells in tumor microenvironment. Comput. Struct. Biotechnol. J. 17, 1\u201313. https:\/\/doi.org\/10.1016\/j.csbj.2018.11.004 (2019).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"94183_CR50","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21147\/j.issn.1000-9604.2016.05.10","volume":"28","author":"J Dong","year":"2016","unstructured":"Dong, J. et al. Prognostic potential of an immune score based on the density of CD8(+) T cells, CD20(+) B cells, and CD33(+)\/p-STAT1(+) double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients. Chin. J. Cancer Res. 28, 543\u2013552. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2016.05.10 (2016).","journal-title":"Chin. J. Cancer Res."},{"key":"94183_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-018-0352-y","volume":"120","author":"H Ma","year":"2019","unstructured":"Ma, H. et al. Interferon-alpha promotes immunosuppression through IFNAR1\/STAT1 signalling in head and neck squamous cell carcinoma. Br. J. Cancer 120, 317\u2013330. https:\/\/doi.org\/10.1038\/s41416-018-0352-y (2019).","journal-title":"Br. J. Cancer"},{"key":"94183_CR52","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3892\/ijo.2019.4779","volume":"54","author":"Y Nakayama","year":"2019","unstructured":"Nakayama, Y. et al. PhosphoSTAT1 expression as a potential biomarker for antiPD1\/antiPDL1 immunotherapy for breast cancer. Int. J. Oncol. 54, 2030\u20132038. https:\/\/doi.org\/10.3892\/ijo.2019.4779 (2019).","journal-title":"Int. J. Oncol."},{"key":"94183_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-009-9990-5","volume":"97","author":"HJ Marcus","year":"2010","unstructured":"Marcus, H. J., Carpenter, K. L., Price, S. J. & Hutchinson, P. J. In vivo assessment of high-grade glioma biochemistry using microdialysis: A study of energy-related molecules, growth factors and cytokines. J. Neurooncol. 97, 11\u201323. https:\/\/doi.org\/10.1007\/s11060-009-9990-5 (2010).","journal-title":"J. Neurooncol."},{"key":"94183_CR54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/a:1022106910017","volume":"61","author":"M Roslin","year":"2003","unstructured":"Roslin, M., Henriksson, R., Bergstrom, P., Ungerstedt, U. & Bergenheim, A. T. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J. Neurooncol. 61, 151\u2013160. https:\/\/doi.org\/10.1023\/a:1022106910017 (2003).","journal-title":"J. Neurooncol."},{"key":"94183_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/onc.2016.198","volume":"36","author":"BI Ratnikov","year":"2017","unstructured":"Ratnikov, B. I., Scott, D. A., Osterman, A. L., Smith, J. W. & Ronai, Z. A. Metabolic rewiring in melanoma. Oncogene 36, 147\u2013157. https:\/\/doi.org\/10.1038\/onc.2016.198 (2017).","journal-title":"Oncogene"},{"key":"94183_CR56","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/pcmr.12000","volume":"25","author":"FV Filipp","year":"2012","unstructured":"Filipp, F. V. et al. Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res. 25, 732\u2013739. https:\/\/doi.org\/10.1111\/pcmr.12000 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"key":"94183_CR57","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/onc.2014.231","volume":"34","author":"T Gelb","year":"2015","unstructured":"Gelb, T. et al. Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas. Oncogene 34, 2711\u20132720. https:\/\/doi.org\/10.1038\/onc.2014.231 (2015).","journal-title":"Oncogene"},{"key":"94183_CR58","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-11-0098","volume":"17","author":"HJ Lee","year":"2011","unstructured":"Lee, H. J. et al. Glutamatergic pathway targeting in melanoma: Single-agent and combinatorial therapies. Clin. Cancer Res. 17, 7080\u20137092. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0098 (2011).","journal-title":"Clin. Cancer Res."},{"key":"94183_CR59","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1523\/JNEUROSCI.19-24-10767.1999","volume":"19","author":"ZC Ye","year":"1999","unstructured":"Ye, Z. C., Rothstein, J. D. & Sontheimer, H. Compromised glutamate transport in human glioma cells: Reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J. Neurosci. 19, 10767\u201310777 (1999).","journal-title":"J. Neurosci."},{"key":"94183_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1423-0127-19-10","volume":"19","author":"K Varini","year":"2012","unstructured":"Varini, K. et al. Mislocalization of the exitatory amino-acid transporters (EAATs) in human astrocytoma and non-astrocytoma cancer cells: Effect of the cell confluence. J. Biomed. Sci. 19, 10. https:\/\/doi.org\/10.1186\/1423-0127-19-10 (2012).","journal-title":"J. Biomed. Sci."},{"key":"94183_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020184","author":"S Mahmoud","year":"2019","unstructured":"Mahmoud, S., Gharagozloo, M., Simard, C. & Gris, D. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells https:\/\/doi.org\/10.3390\/cells8020184 (2019).","journal-title":"Cells"},{"key":"94183_CR62","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1212\/WNL.0b013e318266fa89","volume":"79","author":"TI Yuen","year":"2012","unstructured":"Yuen, T. I. et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 79, 883\u2013889. https:\/\/doi.org\/10.1212\/WNL.0b013e318266fa89 (2012).","journal-title":"Neurology"},{"key":"94183_CR63","doi-asserted-by":"publisher","first-page":"e0195151","DOI":"10.1371\/journal.pone.0195151","volume":"13","author":"M Nagane","year":"2018","unstructured":"Nagane, M. et al. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma. PLoS ONE 13, e0195151. https:\/\/doi.org\/10.1371\/journal.pone.0195151 (2018).","journal-title":"PLoS ONE"},{"key":"94183_CR64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1471-4159.2008.05301.x","volume":"105","author":"H Sontheimer","year":"2008","unstructured":"Sontheimer, H. A role for glutamate in growth and invasion of primary brain tumors. J. Neurochem. 105, 287\u2013295. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05301.x (2008).","journal-title":"J. Neurochem."},{"key":"94183_CR65","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/s0006-2952(02)01218-2","volume":"64","author":"W Rzeski","year":"2002","unstructured":"Rzeski, W., Ikonomidou, C. & Turski, L. Glutamate antagonists limit tumor growth. Biochem. Pharmacol. 64, 1195\u20131200. https:\/\/doi.org\/10.1016\/s0006-2952(02)01218-2 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"94183_CR66","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/s41598-018-24709-0","volume":"8","author":"C Wasinger","year":"2018","unstructured":"Wasinger, C., Hofer, A., Spadiut, O. & Hohenegger, M. Amino acid signature in human melanoma cell lines from different disease stages. Sci. Rep. 8, 6245. https:\/\/doi.org\/10.1038\/s41598-018-24709-0 (2018).","journal-title":"Sci. Rep."},{"key":"94183_CR67","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/jid.2010.126","volume":"130","author":"MN Le","year":"2010","unstructured":"Le, M. N. et al. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J. Investig. Dermatol. 130, 2240\u20132249. https:\/\/doi.org\/10.1038\/jid.2010.126 (2010).","journal-title":"J. Investig. Dermatol."},{"key":"94183_CR68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4049\/jimmunol.178.2.683","volume":"178","author":"Y Ganor","year":"2007","unstructured":"Ganor, Y., Teichberg, V. I. & Levite, M. TCR activation eliminates glutamate receptor GluR3 from the cell surface of normal human T cells, via an autocrine\/paracrine granzyme B-mediated proteolytic cleavage. J. Immunol. 178, 683\u2013692 (2007).","journal-title":"J. Immunol."},{"key":"94183_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2007.01.003","volume":"185","author":"R Pacheco","year":"2007","unstructured":"Pacheco, R., Gallart, T., Lluis, C. & Franco, R. Role of glutamate on T-cell mediated immunity. J. Neuroimmunol. 185, 9\u201319. https:\/\/doi.org\/10.1016\/j.jneuroim.2007.01.003 (2007).","journal-title":"J. Neuroimmunol."},{"key":"94183_CR70","doi-asserted-by":"publisher","first-page":"33352","DOI":"10.1074\/jbc.M401761200","volume":"279","author":"R Pacheco","year":"2004","unstructured":"Pacheco, R. et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J. Biol. Chem. 279, 33352\u201333358. https:\/\/doi.org\/10.1074\/jbc.M401761200 (2004).","journal-title":"J. Biol. Chem."},{"key":"94183_CR71","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","volume":"18","author":"NN Khodarev","year":"2012","unstructured":"Khodarev, N. N., Roizman, B. & Weichselbaum, R. R. Molecular pathways: Interferon\/stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 18, 3015\u20133021. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3225 (2012).","journal-title":"Clin. Cancer Res."},{"key":"94183_CR72","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.4049\/jimmunol.1801152","volume":"202","author":"ML Goodman","year":"2019","unstructured":"Goodman, M. L. et al. Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer. J. Immunol. 202, 3076\u20133086. https:\/\/doi.org\/10.4049\/jimmunol.1801152 (2019).","journal-title":"J. Immunol."},{"key":"94183_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122002","author":"KL Owen","year":"2019","unstructured":"Owen, K. L., Brockwell, N. K. & Parker, B. S. JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression. Cancers https:\/\/doi.org\/10.3390\/cancers11122002 (2019).","journal-title":"Cancers"},{"key":"94183_CR74","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/sj.onc.1205341","volume":"21","author":"S Huang","year":"2002","unstructured":"Huang, S., Bucana, C. D., Van Arsdall, M. & Fidler, I. J. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21, 2504\u20132512. https:\/\/doi.org\/10.1038\/sj.onc.1205341 (2002).","journal-title":"Oncogene"},{"key":"94183_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ijc.26471","volume":"131","author":"R Carretero","year":"2012","unstructured":"Carretero, R. et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int. J. Cancer 131, 387\u2013395. https:\/\/doi.org\/10.1002\/ijc.26471 (2012).","journal-title":"Int. J. Cancer"},{"key":"94183_CR76","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cjp2.55","volume":"2","author":"KK Au","year":"2016","unstructured":"Au, K. K. et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. J. Pathol. Clin. Res. 2, 259\u2013270. https:\/\/doi.org\/10.1002\/cjp2.55 (2016).","journal-title":"J. Pathol. Clin. Res."},{"key":"94183_CR77","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.4161\/cc.9.23.13955","volume":"9","author":"G Dimco","year":"2010","unstructured":"Dimco, G., Knight, R. A., Latchman, D. S. & Stephanou, A. STAT1 interacts directly with cyclin D1\/Cdk4 and mediates cell cycle arrest. Cell Cycle 9, 4638\u20134649. https:\/\/doi.org\/10.4161\/cc.9.23.13955 (2010).","journal-title":"Cell Cycle"},{"key":"94183_CR78","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1128\/mcb.17.9.5328","volume":"17","author":"YE Chin","year":"1997","unstructured":"Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A. & Fu, X. Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell Biol. 17, 5328\u20135337. https:\/\/doi.org\/10.1128\/mcb.17.9.5328 (1997).","journal-title":"Mol. Cell Biol."},{"key":"94183_CR79","doi-asserted-by":"publisher","first-page":"16351","DOI":"10.1074\/jbc.272.26.16351","volume":"272","author":"NK Ossina","year":"1997","unstructured":"Ossina, N. K. et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem. 272, 16351\u201316357. https:\/\/doi.org\/10.1074\/jbc.272.26.16351 (1997).","journal-title":"J. Biol. Chem."},{"key":"94183_CR80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.cgt.7700285","volume":"8","author":"M Baratin","year":"2001","unstructured":"Baratin, M. et al. Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther. 8, 193\u2013202. https:\/\/doi.org\/10.1038\/sj.cgt.7700285 (2001).","journal-title":"Cancer Gene Ther."},{"key":"94183_CR81","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.3892\/ol.2019.10953","volume":"18","author":"T Kikuchi","year":"2019","unstructured":"Kikuchi, T. et al. A subset of patients with MSS\/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-gamma. Oncol. Lett. 18, 5977\u20135985. https:\/\/doi.org\/10.3892\/ol.2019.10953 (2019).","journal-title":"Oncol. Lett."},{"key":"94183_CR82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ncb3090","volume":"17","author":"W Zhou","year":"2015","unstructured":"Zhou, W. et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17, 170\u2013182. https:\/\/doi.org\/10.1038\/ncb3090 (2015).","journal-title":"Nat. Cell Biol."},{"key":"94183_CR83","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.prp.2016.02.020","volume":"212","author":"C Mignogna","year":"2016","unstructured":"Mignogna, C. et al. A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature. Pathol. Res. Pract. 212, 491\u2013499. https:\/\/doi.org\/10.1016\/j.prp.2016.02.020 (2016).","journal-title":"Pathol. Res. Pract."},{"key":"94183_CR84","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","volume":"124","author":"J Condeelis","year":"2006","unstructured":"Condeelis, J. & Pollard, J. W. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263\u2013266. https:\/\/doi.org\/10.1016\/j.cell.2006.01.007 (2006).","journal-title":"Cell"},{"key":"94183_CR85","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","volume":"42","author":"A Sica","year":"2006","unstructured":"Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717\u2013727. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.003 (2006).","journal-title":"Eur. J. Cancer"},{"key":"94183_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041005","author":"E Guadagno","year":"2018","unstructured":"Guadagno, E. et al. Role of macrophages in brain tumor growth and progression. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms19041005 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"94183_CR87","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1074\/jbc.M113.535765","volume":"289","author":"L He","year":"2014","unstructured":"He, L. & Marneros, A. G. Doxycycline inhibits polarization of macrophages to the proangiogenic M2-type and subsequent neovascularization. J. Biol. Chem. 289, 8019\u20138028. https:\/\/doi.org\/10.1074\/jbc.M113.535765 (2014).","journal-title":"J. Biol. Chem."},{"key":"94183_CR88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.coph.2017.04.007","volume":"35","author":"N Dehne","year":"2017","unstructured":"Dehne, N., Mora, J., Namgaladze, D., Weigert, A. & Brune, B. Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr. Opin. Pharmacol. 35, 12\u201319. https:\/\/doi.org\/10.1016\/j.coph.2017.04.007 (2017).","journal-title":"Curr. Opin. Pharmacol."},{"key":"94183_CR89","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-016-2169-y","volume":"129","author":"A Neal","year":"2016","unstructured":"Neal, A. et al. Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas. J. Neurooncol. 129, 259\u2013267. https:\/\/doi.org\/10.1007\/s11060-016-2169-y (2016).","journal-title":"J. Neurooncol."},{"key":"94183_CR90","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/brain\/awt345","volume":"137","author":"J Pallud","year":"2014","unstructured":"Pallud, J. et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137, 449\u2013462. https:\/\/doi.org\/10.1093\/brain\/awt345 (2014).","journal-title":"Brain"},{"key":"94183_CR91","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.nicl.2019.101694","volume":"22","author":"A Neal","year":"2019","unstructured":"Neal, A. et al. Glutamate weighted imaging contrast in gliomas with 7Tesla magnetic resonance imaging. Neuroimage Clin. 22, 101694. https:\/\/doi.org\/10.1016\/j.nicl.2019.101694 (2019).","journal-title":"Neuroimage Clin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94183-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:33:29Z","timestamp":1670067209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94183-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94183"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94183-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14644"}}